<DOC>
	<DOC>NCT00820092</DOC>
	<brief_summary>1. To investigate the safety and tolerability of Xerecept during and following a 24-hour intravenous administration to healthy Japanese to healthy Japanese and Caucasian subjects 2. To compare the PK profile of hCRF during and following a 24-hour intravenous Xerecept administration between healthy Japanese and Caucasian subjects</brief_summary>
	<brief_title>Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers</brief_title>
	<detailed_description>none needed</detailed_description>
	<criteria>Healthy male and female Japanese subjects who are citizens of Japan Healthy male and female Caucasian subjects Age range 2045 years BMI &gt;19 and &lt;27 kg/m squared Female subjects must not be pregnant at the time of study and use adequate birth control methods before,during and 4 weeks after the study Subjects must be negative for HCV and HIV Subjects must have negative urine tests for drugs of abuse and alcohol at screening Subjects must not have any clinically significant medical conditions</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Xerecept</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Japanese versus Caucasians</keyword>
</DOC>